Aging and the problems that come with it
According to recent data, approximately 46 million people in the United States are over 65 years of age. This means that 46 million and an increasing number of people are concerned about the changes that come with aging. Aging does not only cause aesthetic issues such as wrinkles, balding, greying hair or sagging skin. It is estimated that the causative agents behind the death of more than two-thirds of people are age-related factors. Chronic illnesses such as diabetes, hypertension, cardiovascular diseases, cancer, and many more deadly diseases are all a result of aging.
What is BioViva?
BioViva USA, Inc. is a diagnostics and prognostics platform company. It was established with the purpose of advancing the development of drugs and treatments that could impact human lifespan. BioViva has already come up with a list of biomarkers of aging including molecular, physiological, anatomical, clinical, and qualitative markers. It has also joined forces with other fields such as clinicians, companies, and biomedical scientists to design protocols for adaptive clinical trials.
The Research and Its Purpose
Professor at Rutgers New Jersey Medical School, Hua Zhu and his postdoc Dabbu Jaijyan, are the men behind the research. They are endeavoring to confront the challenges of the biological aging process with an aim to reverse aging itself. They plan to achieve this feat by developing a therapeutic instrument. This tool would reinforce the fundamental repair and regeneration processes of the cell.
Zhu has stated, “The proposed research has great implication for people and governments all over the world seeking a cost-effective preventive solution for all the major diseases of aging. If our project succeeds, it could lead to clinical trials to test the therapeutic potential of recombinant virus expressing multiple anti-aging factors.”
Financed by BioViva USA, the research team has already begun a strategy to develop recombinant mouse cytomegalovirus (R-MCMV). The goal is to express the anti-aging and regenerative factors within it.
The Goals of the Research
The short-term goals of the study are to lengthen the lifecycle of primary human cells and organoids. Whereas short-term, the aim is to create a platform for clinical trial studies. It plans to do so by operating novel human cytomegalovirus (HCMV) as a vector to innovate a multi-gene therapeutic aging vaccine.
Since the idea was first put into motion, BioiViva has as of yet already applied for the patent for the idea. After analyzing the results of the study, the company will initiate the development of this innovative vaccine. This vaccine could put an end to the detrimental impact of aging. BioViva has the vision to unveil the vaccine as soon as possible with a goal to solve the anti-aging burdens of our modern society.
The research studies two herpes viruses, human cytomegalovirus (HCMV) and Varicella-Zoster virus (VZV). It analyzes the pathogenesis of HCMV and VZV. More specifically, it studies the way these viruses network with host cells, replicate, and consequently cause disease. The research lab has all the essential tools to produce recombinant viruses for vaccine development utilizing recombinant bacterial artificial chromosome (BAC) technology.
Zhu, the research leader states cytomegalovirus (CMV) has been proven safe for human clinical studies. The research focuses on designing vaccines for human diseases associated with aging. The research lab has a platform for expressing a gene that could potentially prevent or minimize the disease outcome.
What could the success of the research mean?
According to Elizabeth Parrish, CEO of BioViva “This research is poised to develop a new class of vaccines and redesign how we treat aging, making it easier for people to stay healthy longer. Over 100,000 people die of aging every day, and hundreds of millions suffer from chronic disease. This vaccine has the potential to forge a better way forward, with less suffering.”